Lideramos el cambio de paradigma que supondrá diseñar soluciones terapéuticas a partir de la microbiota intestinal.
After finishing our Phase III clinical trial, ICD-01, we will be the first company to market the first gut microbiota-based biologic in the EU to treat Clostridioides difficile infections, including both primary episodes and recurrences.
We have other clinical trials underway, for different indications such as the treatment of metabolic dysfunction associated with steatohepatitis (MASH), for acute uncomplicated diverticulitis and a proof of concept for the treatment of metastatic colorectal cancer.